BRIDGEWATER, N.J.–(BUSINESS WIRE) April 13, 2022 –Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s…Original Article
FDA Approves Alymsys (bevacizumab-maly), a Biosimilar to Avastin
